Arcalyst Approval History
FDA Approved: Yes (First approved February 27, 2008)
Brand name: Arcalyst
Generic name: rilonacept
Dosage form: Injection
Previous Name: Interleukin-1 Trap
Company: Regeneron Pharmaceuticals, Inc.
Treatment for: Cryopyrin-Associated Periodic Syndromes
Arcalyst (rilonacept) is an interleukin-1 inhibitor for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
Development History and FDA Approval Process for Arcalyst
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.